Showing results (101-110 of 168) with videos related to
Sort By:
Pageof 17
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 31, 2008
Cognitive-behavioral therapy for sleep disturbance in patients undergoing peritoneal dialysis: a pilot randomized controlled trialHung-Yuan Chen, Chih-Kang Chiang, Hsi-Hao Wang, et al.American Journal of Nephrology|June 7, 2008
Clinical utility of malnutrition-inflammation score in maintenance hemodialysis patients: focus on identifying the best cut-off pointLi-chun Ho, His-Hao Wang, Yu-Sen Peng, et al.Oncotarget|March 10, 2016
Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitroShing-Hwa Liu, Ching-Chin Yang, Ding-Cheng Chan, et al.Nephrology (Carlton, Vic.)|December 8, 2016
Diabetes mellitus, superoxide dismutase and peroxisome proliferator activated receptor gamma polymorphisms modify the outcome of end-stage renal disease patients of Han Chinese originChia-Ter Chao, Jenq-Wen Huang, Chih-Kang Chiang, et al.Blood Purification|January 19, 2011
Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosisJenq-Wen Huang, Chung-Jen Yen, Hon-Yen Wu, et al.Blood Purification|January 25, 2005
Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patientsChih-Kang Chiang, Tai-I Ho, Shih-Ping Hsu, et al.Plos One|March 8, 2013
Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney diseaseFan-Chi Chang, Tai-Shuan Lai, Chih-Kang Chiang, et al.Disease Markers|March 19, 2015
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal diseaseChia-Ter Chao, Yen-Ching Chen, Chih-Kang Chiang, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 27, 2021
Angiopoietin-2 is associated with metabolic syndrome in chronic kidney diseaseFan-Chi Chang, Ming-Ching Lee, Chih-Kang Chiang, et al.American Journal of Nephrology|November 1, 2008
Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effectsChih-Kang Chiang, Shao-Yu Yang, Yu-Sen Peng, et al.Pageof 17